Skip to content
Open access · CC-BY via OpenAlex

Emerging therapeutic roles for NAD<sup>+</sup> metabolism in mitochondrial and age‐related disorders

Sarika Srivastava

Clinical and Translational Medicine · 2016 · ▲ 189 citations

Abstract

Nicotinamide adenine dinucleotide (NAD(+)) is a central metabolic cofactor in eukaryotic cells that plays a critical role in regulating cellular metabolism and energy homeostasis. NAD(+) in its reduced form (i.e. NADH) serves as the primary electron donor in mitochondrial respiratory chain, which involves adenosine triphosphate production by oxidative phosphorylation. The NAD(+)/NADH ratio also regulates the activity of various metabolic pathway enzymes such as those involved in glycolysis, Kreb's cycle, and fatty acid oxidation. Intracellular NAD(+) is synthesized de novo from L-tryptophan, although its main source of synthesis is through salvage pathways from dietary niacin as precursors. NAD(+) is utilized by various proteins including sirtuins, poly ADP-ribose polymerases (PARPs) and cyclic ADP-ribose synthases. The NAD(+) pool is thus set by a critical balance between NAD(+) biosynthetic and NAD(+) consuming pathways. Raising cellular NAD(+) content by inducing its biosynthesis or inhibiting the activity of PARP and cADP-ribose synthases via genetic or pharmacological means lead to sirtuins activation. Sirtuins modulate distinct metabolic, energetic and stress response pathways, and through their activation, NAD(+) directly links the cellular redox state with signaling and transcriptional events. NAD(+) levels decline with mitochondrial dysfunction(definition) and reduced NAD(+)/NADH ratio is implicated in mitochondrial disorders, various age-related pathologies as well as during aging. Here, I will provide an overview of the current knowledge on NAD(+) metabolism including its biosynthesis, utilization, compartmentalization and role in the regulation of metabolic homoeostasis. I will further discuss how augmenting intracellular NAD(+) content increases oxidative metabolism to prevent bioenergetic and functional decline in multiple models of mitochondrial diseases and age-related disorders, and how this knowledge could be translated to the clinic for human relevance.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1186/s40169-016-0104-7
Canonical
link ↗
Fetched
2026-06-01 MST

Cite this

APA
Srivastava, S. (2016). Emerging therapeutic roles for NAD<sup>+</sup> metabolism in mitochondrial and age‐related disorders. <em>Clinical and Translational Medicine</em>. https://doi.org/10.1186/s40169-016-0104-7
Vancouver
Srivastava S. Emerging therapeutic roles for NAD<sup>+</sup> metabolism in mitochondrial and age‐related disorders. Clinical and Translational Medicine. 2016. doi:10.1186/s40169-016-0104-7.
BibTeX
@article{sarika2016Emergi, title = {Emerging therapeutic roles for NAD<sup>+</sup> metabolism in mitochondrial and age‐related disorders}, author = {Sarika Srivastava}, journal = {Clinical and Translational Medicine}, year = {2016}, doi = {10.1186/s40169-016-0104-7}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings